Home / Market News / $SYRE
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Deutsche Bank Adjusts Spyre Therapeutics Price Target to $141 From $123, Maintains Buy Rating

Nov 13, 2026, 2:38 PM UTC · Primary ticker $SYRE

Deutsche Bank has increased its price target for Spyre Therapeutics from $123 to $141, while maintaining a Buy rating. This adjustment reflects the firm's updated valuation and positive outlook on the company's market position, suggesting a continued bullish sentiment from the analyst.

Deutsche Bank updated its outlook on Spyre Therapeutics, raising the price target from $123 to $141 and reaffirming a Buy rating. This action signals a continued positive assessment of Spyre Therapeutics' prospects by a major financial institution. For traders, this could lead to short-term positive sentiment and potentially increased buying interest in SYRE shares, as it indicates an analyst's belief in the company's growth potential. The long-term implications depend on whether the company's fundamentals and future performance align with this increased valuation. A key opportunity for traders is to capitalize on any immediate upward movement, while the risk lies in the possibility that the market may not fully embrace this new target or that future company news could negate this positive outlook.

$SYRE positive Price target increase and maintained Buy rating
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.